血管活性药物和败血症休克中的微循环:一个范围审查
Shyama Sathianathan1, Saloni Sachar2, Jana Berro2
1Department of Pulmonary Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH.
Critical care medicine
|January 13, 2026
概括
血管活性药物对败血性休克微循环有不同的影响. 目前的研究突出显示,整体血流和微血管输液之间存在分离,需要进行标准化研究以获得更好的患者结果.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学 是一个学科.
- 血液动力学 血液动力学
背景情况:
- 败血栓休克管理越来越多地侧重于输液导向护理.
- 了解血管活性药物对微循环的影响对于优化复苏策略至关重要.
研究的目的:
- 综合当前关于血管活性剂对败血性休克中微血管输液影响的证据.
- 确定这个研究领域的知识差距.
主要方法:
- 在主要数据库 (MEDLINE,Embase,Cochrane) 中进行全面的文献搜索.
- 包括接受血管活性治疗的成年败血症休克患者,并进行微循环测量.
- 提取关于研究设计,患者人口统计,药物和输液指标的数据.
主要成果:
- 33项研究分析了各种血管活性药物和微循环技术.
- 早期患者招募 (24小时内) 与更明显的微循环变化相关.
- 全球血液动力学和微血管输液在61%的病例中显示出异常.
- 上腺素,血管压素,特里普林素和levosimendan显示出了依赖于环境的微循环改善.
- 多布他胺可以改善输液,但需要进一步的研究.
结论:
- 了解血管活性剂如何影响败血性休克中微循环仍然存在重大挑战.
- 标准化研究协议和护理点监测对于推进以结果为导向的复苏至关重要.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
1.5K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.5K
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Autoregulation of Blood Flow
7.4K
Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
7.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915


